Conclusions:
meningitis, deaths, death, Meningitis
MENINGITIS, DISEASE, BACTERIAL MENINGITIS, MENINGITIS
NmCV-5 elicits comparable immune responses to all 4 serotypes in common with MenACWY-D as well as to serogroup X without evident safety concerns.The Global Roadmap for Defeating Meningitis by 2030 was endorsed by the World Health Assembly in November 2020 and aims to eliminate epidemic bacterial meningitis, and to reduce rates of vaccine preventable disease by 50%, and death by 70%, before the end of the decade.In 2019, there were estimated to be over 2.5 million cases of meningitis worldwide, resulting in more than 236 000 deaths.Although four quadrivalent meningococcal ACWY conjugate vaccines are licensed and prequalified by WHO, their use in the African meningitis belt has been limited by supply and cost constraints.Here we report the results of a phase 3 trial of NmCV-5 conducted in 2- to 29-year-olds, the target age-groups for meningococcal outbreak response campaigns, in Mali and The Gambia. The trial aimed to demonstrate the safety and immunological non-inferiority of NmCV-5 compared to a licensed, WHO prequalified quadrivalent meningococcal conjugate vaccine (MenACWY-D [Menactra